Andere Sprachen Hofseth BioCare ASA

Aktien

A1JWL4

NO0010598683

HBC

Markt geschlossen - Oslo Bors Andere Börsenplätze 16:45:00 04.07.2024			% 5 Tage	% 1. Jan.
2 ^NOK	0.00%		-1.48%	-23.66%

11.06.	Hofseth Biocare ASA kündigt die Ernennung von Lithy One- Health Group Technology Co. Ltd. als zusätzlichen Vertriebspartner in China	CI
16.05.	Hofseth BioCare ASA meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Hofseth BioCare to Transfer Patent for New Asthma Drug Candidate to Unit	02.07.
Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.	02.07.
Hofseth Biocare ASA Announces the Appointment of Lithy One- Health Group Technology Co. Ltd as an Additional Distributor in China	11.06.
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY	11.06.
Hofseth BioCare ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	16.05.
Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT	16.05.
Hofseth Biocare ASA: Annual General Meeting completed	10.05.
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024	19.04.
Hofseth Biocare ASA: HBC ANNUAL REPORT 2023	19.04.
Hofseth Biocare ASA: DISCLOSURE OF LARGE SHAREHOLDING	05.04.
Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION	21.03.
Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION	21.03.
Hofseth Biocare ASA: CHAIR KRISTIN FJELLBY GRUNG STEPS DOWN	14.03.
Hofseth BioCare ASA Announces Board Changes	14.03.
Hofseth BioCare ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	09.02.
Hofseth BioCare ASA Reports Earnings Results for the Full Year Ended December 31, 2023	09.02.
Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT	09.02.
Hofseth Biocare ASA: FOURTH QUARTER 2023 AND FULL YEAR FINANCIAL REPORT	09.02.
Hofseth Biocare ASA: HBC Immunology Inc successfully completes first animal model of prostate cancer with FT-005 in combination with hormonal (anti-androgen) therapy demonstrating significant anti-tumour activity	06.02.
Hofseth Biocare ASA: SHARE CAPITAL INCREASE REGISTERED	09.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Hofseth BioCare ASA

Aktien

A1JWL4

NO0010598683

HBC

Andere Sprachen

Filter